Ustekinumab treatment for hidradenitis suppurativa

Takeda, Kouji; Kikuchi, Katsuko; Kanazawa, Yoshitake; Yamasaki, Kenshi; Aiba, Setsuya

doi:10.1111/1346-8138.15122

Cited by 20 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of HS therapy, biologic agents, particularly targeting tumour necrosis factor alpha (TNFα), are now an integral part of the management of moderate to severe disease [79][80][81]. Although clinical benefit has been reported with several biologics, including infliximab [82], ustekinumab [83] and secukinumab [84], only adalimumab is licensed at present for the treatment of moderate to severe HS.…”

Section: The Cutaneous And/or Gastrointestinal Microbiomes As a Theramentioning

confidence: 99%

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

Langan

Recke

Bokor-Billmann

et al. 2020

IJMS

View full text Add to dashboard Cite

The development of next generation sequencing, coupled with advances in bio-informatics, has provided new insights into the role of the cutaneous microbiome in the pathophysiology of a range of inflammatory skin diseases. In fact, it has even been suggested that the identification of specific skin microbial signatures may not only be useful in terms of diagnosis of skin diseases but they may also ultimately help inform personalised treatment strategies. To date, research investigating the role of microbiota in the development of inflammatory skin diseases has largely focused on atopic eczema and psoriasis vulgaris. The role of the microbiome in Hidradenits suppurativa (HS)-also known as acne inversa-a chronic auto-inflammatory skin disease associated with significant morbidity, has received comparatively little attention. This is despite the fact that antimicrobial therapy plays a central role in the treatment of HS. After briefly outlining the clinical features of HS and current treatment strategies, we move on to review the evidence of microbial dysbiosis in HS pathophysiology. We conclude by outlining the potential for metagenomic studies to deepen our understanding of HS biology but more importantly to identify novel and much needed treatment strategies.scoring and the HS severity index. Whilst the precise incidence and prevalence of HS is unclear [8], due partly to the diagnostic difficulty associated with HS and the use of both registry data and self-report questionnaires [9]. Garg et al. reported a prevalence of 0.1% in a US-based population analysis, leading the authors to conclude that HS is an uncommon but not rare disease, with over-representation in young, female and African American patients [10]. The current multi-modal treatment approach includes the use of intralesional steroids, surgical and laser therapy, topical and systemic medical antimicrobial therapy and biologic treatments [11].Sartorius scoring and the HS severity index. Whilst the precise incidence and prevalence of HS is unclear [8], due partly to the diagnostic difficulty associated with HS and the use of both registry data and self-report questionnaires [9]. Garg et al. reported a prevalence of 0.1% in a US-based population analysis, leading the authors to conclude that HS is an uncommon but not rare disease, with over-representation in young, female and African American patients [10]. The current multi-modal treatment approach includes the use of intralesional steroids, surgical and laser therapy, topical and systemic medical antimicrobial therapy and biologic treatments [11].

show abstract

Section: The Cutaneous And/or Gastrointestinal Microbiomes As a Theramentioning

confidence: 99%

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

Langan

Recke

Bokor-Billmann

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…8 Candidates for this treatment are young adults (around 35 years of age) with moderate to severe HS, who have previously received multiple treatments for HS. 3 The mean age of our patients was 12 years and all of them had a Hurley stage III HS. All patients had been previously treated with adalimumab, with primary or secondary failure.…”

Section: Discussionmentioning

confidence: 94%

“…Despite of the lack of randomized clinical trials that support the efficacy and safety of ustekinumab in HS, some case reports and case series have been published in the literature [3][4][5][6][7][8][9] ; to the best of our knowledge, 49 cases have been published to date. The dosage used was variable, but most of the patients received the psoriasis dosage regimen.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

Sánchez‐Martínez

Ruiz

Moneva-Leniz

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, systemic, inflammatory dermatosis which lacks curative treatment. Its management can be challenging, thus a variety of therapies are commonly used, such as antibiotics, anti-inflammatory drugs, retinoids, surgery and biological treatments. Adalimumab is the only approved biological therapy for HS, while secukinumab, risankizumab or guselkumab are currently under investigation with ongoing trials for HS. 1,2 To our knowledge, there are currently no clinical trials being conducted to assess the efficacy of ustekinumab in HS. The present study provides some extra evidence about the effectiveness and safety of ustekinumab in HS.

show abstract

“…Ustekinumab is a human monoclonal antibody that acts by inhibiting the p40 subunit on IL-12 and IL-23 [ 127 , 135 ]. In a Phase II open-label study involving 17 patients, patients showed moderate-to-marked improvement achieving HiSCR in almost 40% of cases [ 136 ].…”

Section: Resultsmentioning

confidence: 99%

Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa

Duca

Morelli

Bennardo

et al. 2020

IJMS

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting areas with a high density of apocrine glands and characterized by subcutaneous nodules that may evolve into fistulas with pus secretion. Methods: The aim of this review is to investigate all current knowledge on cytokine regulation in the pathogenesis of HS. A systematic literature research using the words “cytokine”, “interleukin”, “pathway”, and “hidradenitis suppurativa” was performed in PubMed/Medline and Scopus/Embase databases. A search of the clinicaltrials.gov website for interventional recruiting and completed trials including the term “hidradenitis suppurativa” was also performed up to August 2020. We will discuss the pathogenetic role of various cytokines in HS and potential therapeutic targets for this debilitating disease. Results: The pathophysiology underlying this complex condition has not been clearly defined. An upregulation of various cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-17, IL-23, and other molecules seems to be related to this inflammatory condition. Various cells, such as lymphocytes T Helper 1 and 17 and keratinocytes seem to be involved in the genesis of this condition. Conclusions: Several future studies and clinical trials are necessary in order to have new knowledge about HS and to properly treat this complex condition.

show abstract

Ustekinumab treatment for hidradenitis suppurativa

Cited by 20 publications

References 16 publications

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa

Contact Info

Product

Resources

About